Quarterly ResultMay 15, 2026, 08:22 AM
Indaptus Therapeutics Reports Q1 Net Loss $2.54M; Going Concern Doubt
AI Summary
Indaptus Therapeutics reported a net loss of $2.54 million for the first quarter of 2026, an improvement from a $4.53 million loss in the prior year. However, the company's cash and cash equivalents significantly declined to $1.50 million, leading to substantial doubt about its ability to continue as a going concern. Indaptus is actively exploring strategic transactions, including investments or acquisitions, to create future growth opportunities and secure additional capital.
Key Highlights
- Net loss for Q1 2026 was $2.54 million, down from $4.53 million in Q1 2025.
- Cash and cash equivalents stood at $1.50 million as of March 31, 2026, down from $8.51 million at year-end 2025.
- Company incurred $7.01 million cash used in operating activities in Q1 2026.
- Accumulated deficit reached $83.83 million as of March 31, 2026.
- Substantial doubt exists regarding the company's ability to continue as a going concern.
- All preferred stock was converted into 111 million common shares during Q1 2026.
- Warrant repricing resulted in a $0.41 million expense in Q1 2026.
- Research and development expenses decreased to $0.49 million in Q1 2026 from $2.81 million in Q1 2025.
Price Impact
More from INDP